ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.21
-0.05%
US Tech 100
19,483.60
-0.49%
S&P 500
5,744.65
-0.01%
US Dollar vs CAD
1.35108
0.25%
Bitcoin
65,937.16
1.16%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Genprex Inc (GNPX)

  7. Genprex Inc (GNPX) News

GNPX

Genprex (GNPX)

Genprex Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GNPX
DateTimeSourceHeadlineSymbolCompany
09/26/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
09/23/20248:29AMPR Newswire (US)Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and DiabetesNASDAQ:GNPXGenprex Inc
09/19/20248:29AMPR Newswire (US)Genprex Announces Formation of Mesothelioma Clinical Advisory BoardNASDAQ:GNPXGenprex Inc
09/09/20248:29AMPR Newswire (US)Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsNASDAQ:GNPXGenprex Inc
09/04/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
09/04/20248:29AMPR Newswire (US)Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 DiabetesNASDAQ:GNPXGenprex Inc
09/03/20247:15AMPR Newswire (US)Genprex to Present and Participate at Upcoming September Investor and Industry ConferencesNASDAQ:GNPXGenprex Inc
08/16/20243:18PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GNPXGenprex Inc
08/15/20248:30AMPR Newswire (US)Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical TrialsNASDAQ:GNPXGenprex Inc
08/14/20248:25AMPR Newswire (US)Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung CancerNASDAQ:GNPXGenprex Inc
08/13/20247:38AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
08/13/20247:31AMPR Newswire (US)Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat CancersNASDAQ:GNPXGenprex Inc
08/09/20243:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GNPXGenprex Inc
08/08/20247:30AMPR Newswire (US)Genprex to Present at the August Sidoti Microcap ConferenceNASDAQ:GNPXGenprex Inc
06/27/20247:31AMPR Newswire (US)Genprex Issues Stockholder Letter and Provides 2024 Corporate UpdateNASDAQ:GNPXGenprex Inc
05/30/20247:31AMPR Newswire (US)Genprex to Present at the 2024 BIO International ConventionNASDAQ:GNPXGenprex Inc
05/20/20243:35PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GNPXGenprex Inc
05/15/20243:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GNPXGenprex Inc
05/14/20247:31AMPR Newswire (US)Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
05/13/20247:31AMPR Newswire (US)Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of DirectorsNASDAQ:GNPXGenprex Inc
05/09/20247:11AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
05/08/20245:08PMPR Newswire (US)Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerNASDAQ:GNPXGenprex Inc
05/01/20247:31AMPR Newswire (US)Genprex to Present and Participate at Upcoming May Investor and Industry ConferencesNASDAQ:GNPXGenprex Inc
04/09/20247:31AMPR Newswire (US)Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingNASDAQ:GNPXGenprex Inc
04/03/20247:31AMPR Newswire (US)Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
04/02/20247:31AMPR Newswire (US)Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery SystemNASDAQ:GNPXGenprex Inc
03/22/20243:10PMPR Newswire (US)Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
03/19/202412:24PMPR Newswire (US)Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
03/19/20247:36AMPR Newswire (US)Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
03/12/20248:01AMPR Newswire (US)Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat CancersNASDAQ:GNPXGenprex Inc
 Showing the most relevant articles for your search:NASDAQ:GNPX

Your Recent History

NASDAQ
FBSMCX
FTP Travel And Destinati...
KRKN
SUIUSD
SUI Network
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved